-
Je něco špatně v tomto záznamu ?
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
A. Oaknin, JY. Lee, V. Makker, DY. Oh, S. Banerjee, A. González-Martín, KH. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, S. Puvvada, A. Smith, F. Meric-Bernstam
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- imunohistochemie MeSH
- imunokonjugáty * terapeutické užití škodlivé účinky MeSH
- kamptothecin * analogy a deriváty terapeutické užití aplikace a dávkování škodlivé účinky MeSH
- klinické zkoušky, fáze II jako téma MeSH
- lidé MeSH
- nádory * farmakoterapie metabolismus patologie MeSH
- protinádorové látky imunologicky aktivní * terapeutické užití MeSH
- receptor erbB-2 * metabolismus MeSH
- sekundární analýza dat MeSH
- trastuzumab * terapeutické užití škodlivé účinky MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
of the original article, 'Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02'. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate, which is a chemotherapy with a linker (deruxtecan) joined to an antibody (trastuzumab). Trastuzumab binds to the human epidermal growth factor receptor 2 (HER2) protein on cancer cells, where it releases the chemotherapy to kill these cells. The DESTINY-PanTumor02 clinical study tested the effectiveness of T-DXd for people with various HER2-expressing cancers and the safety of treatment. Previous results from DESTINY-PanTumor02 showed that T-DXd had antitumor activity, and the greatest effects were seen in people with the highest tumor level of HER2 [defined as immunohistochemistry (IHC) 3+]. In this previous analysis, the HER2 expression was measured at a central laboratory. In clinical practice, HER2 expression will likely be measured at a local laboratory, so understanding whether T-DXd has similar effects regardless of how HER2 expression is measured is important. Here, we looked at the effects of T-DXd based on the HER2 test result used to determine a person's eligibility for the study, which could be measured using a local or central laboratory. In people with IHC 3+ tumors (where HER2 was measured at a local or central laboratory), 51% had a decrease in the size or number of tumors, according to established criteria (referred to as an objective response), while, in people with IHC 2+ tumors, 26% had an objective response. Side effects with T-DXd were consistent with previous studies. These results confirm T-DXd has antitumor effects in HER2-expressing cancers where the HER2 expression is measured by a local or central laboratory.
Cancer Research Institute Seoul National University College of Medicine Seoul Republic of Korea
Department of Medical Oncology Hospital Universitario 12 de Octubre Madrid Spain
Department of Medicine Weill Cornell Medical College New York NY USA
Department of Oncology and Hemato Oncology Università degli Studi di Milano Milan Italy
Department of Oncology Palacký University Medical School and University Hospital Olomouc Czechia
Gynaecology Unit The Royal Marsden NHS Foundation Trust London UK
Gynecologic Medical Oncology Service Memorial Sloan Kettering Cancer Center New York NY USA
Healthcare Department Moscow City Oncology Hospital No 62 Moscow Russian Federation
Institute of Cancer Research London UK
Medical Oncology Service Vall d'Hebron Barcelona Hospital Campus Barcelona Spain
Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda Milan Italy
Oncology Biometrics Oncology R and D AstraZeneca Cambridge UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015932
- 003
- CZ-PrNML
- 005
- 20250731091351.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12325-024-03080-9 $2 doi
- 035 __
- $a (PubMed)40048102
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Oaknin, Ana $u Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain $1 https://orcid.org/0000000235927194
- 245 10
- $a Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 / $c A. Oaknin, JY. Lee, V. Makker, DY. Oh, S. Banerjee, A. González-Martín, KH. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, S. Puvvada, A. Smith, F. Meric-Bernstam
- 520 9_
- $a of the original article, 'Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02'. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate, which is a chemotherapy with a linker (deruxtecan) joined to an antibody (trastuzumab). Trastuzumab binds to the human epidermal growth factor receptor 2 (HER2) protein on cancer cells, where it releases the chemotherapy to kill these cells. The DESTINY-PanTumor02 clinical study tested the effectiveness of T-DXd for people with various HER2-expressing cancers and the safety of treatment. Previous results from DESTINY-PanTumor02 showed that T-DXd had antitumor activity, and the greatest effects were seen in people with the highest tumor level of HER2 [defined as immunohistochemistry (IHC) 3+]. In this previous analysis, the HER2 expression was measured at a central laboratory. In clinical practice, HER2 expression will likely be measured at a local laboratory, so understanding whether T-DXd has similar effects regardless of how HER2 expression is measured is important. Here, we looked at the effects of T-DXd based on the HER2 test result used to determine a person's eligibility for the study, which could be measured using a local or central laboratory. In people with IHC 3+ tumors (where HER2 was measured at a local or central laboratory), 51% had a decrease in the size or number of tumors, according to established criteria (referred to as an objective response), while, in people with IHC 2+ tumors, 26% had an objective response. Side effects with T-DXd were consistent with previous studies. These results confirm T-DXd has antitumor effects in HER2-expressing cancers where the HER2 expression is measured by a local or central laboratory.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
- 650 12
- $a kamptothecin $x analogy a deriváty $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D002166
- 650 12
- $a imunokonjugáty $x terapeutické užití $x škodlivé účinky $7 D018796
- 650 _2
- $a imunohistochemie $7 D007150
- 650 12
- $a nádory $x farmakoterapie $x metabolismus $x patologie $7 D009369
- 650 12
- $a receptor erbB-2 $x metabolismus $7 D018719
- 650 12
- $a trastuzumab $x terapeutické užití $x škodlivé účinky $7 D000068878
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a klinické zkoušky, fáze II jako téma $7 D017322
- 650 _2
- $a sekundární analýza dat $7 D000094422
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lee, Jung-Yun $u Department of Obstetrics and Gynecology, Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
- 700 1_
- $a Makker, Vicky $u Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA $u Department of Medicine, Weill Cornell Medical College, New York, NY, USA
- 700 1_
- $a Oh, Do-Youn $u Seoul National University Hospital, Seoul, Republic of Korea $u Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea $u Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea
- 700 1_
- $a Banerjee, Susana $u Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK $u Institute of Cancer Research, London, UK
- 700 1_
- $a González-Martín, Antonio $u Medical Oncology Department and Programme in Solid Tumours-CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, Spain
- 700 1_
- $a Jung, Kyung Hae $u Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 700 1_
- $a Ługowska, Iwona $u Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Manso, Luis $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
- 700 1_
- $a Manzano, Aránzazu $u Experimental Therapeutics in Cancer (UTEC), Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacký University Medical School and University Hospital, Olomouc, Czechia
- 700 1_
- $a Siena, Salvatore $u Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy $u Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Stroyakovskiy, Daniil $u Healthcare Department, Moscow City Oncology Hospital No. 62, Moscow, Russian Federation
- 700 1_
- $a Fielding, Anitra $u Oncology R&D, AstraZeneca, Gaithersburg, MD, USA
- 700 1_
- $a Puvvada, Soham $u Oncology R&D, AstraZeneca, Gaithersburg, MD, USA
- 700 1_
- $a Smith, Ann $u Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK
- 700 1_
- $a Meric-Bernstam, Funda $u Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. fmeric@mdanderson.org
- 773 0_
- $w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 42, č. 5 (2025), s. 2015-2018
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40048102 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091345 $b ABA008
- 999 __
- $a ok $b bmc $g 2366640 $s 1253057
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 42 $c 5 $d 2015-2018 $e 20250306 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
- LZP __
- $a Pubmed-20250708
